Marsh & McLennan Companies, Inc. vs Tilray Brands Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $189.15 (market cap $91.27B), while Tilray Brands Inc trades at $4.69 (market cap $649.42M). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 140.5× Tilray Brands Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| MRSH | TLRY | |
|---|---|---|
Market Cap | $91.27B | $649.42M |
Sector | Financials | Health |
52-Week High | $211.21 | $21.00 |
52-Week Low | $157.32 | $3.88 |
Enterprise Value | $111.95B | $816.55M |
Dividend Yield | 2.07% | — |
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $190.79, down 0.45% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat estimates with EPS of $2.96 versus $2.88 expected, driven by 6% revenue growth. The company announced the acquisition of Accel to expand Midwest operations, enhancing its insurance and consulting services. Valuation metrics show a P/E of 23.35 and ROE of 25.72%, reflecting robust profitability.
Outlook remains positive with a consensus price target of $202.89, offering ~6% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Ashton Thomas Securities added positions. The stock presents a growth opportunity amid strategic expansions, though investors should monitor expense management and competitive dynamics.
TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.
Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.
Trailing returns across standard periods
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →